Novartis' Zelnorm is back, but only through a restricted-access program.
Severin Schwan takes over at Roche
Spending expected to increase mildly in the short term
In the wake of a high-profile death from counterfeit drugs, the industry reacts
How a $65,000 dinner tab led to new reporting rules for Australian pharma
...And the spurned suitor won't take "No" for an answer
But is the pharma-biotech vaccine deal a prelude to a takeover?
Blockbuster antidepressants linked to bone loss in seniors
Catching up with the first ouchless fast test on National HIV Testing Day
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial